furosemide has been researched along with Dyspnea in 85 studies
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.
furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.
Dyspnea: Difficult or labored breathing.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aerosol furosemide may be an option to treat refractory dyspnea, though doses, methods of delivery, and outcomes have been variable." | 9.34 | Controlled Delivery of 80 mg Aerosol Furosemide Does Not Achieve Consistent Dyspnea Relief in Patients. ( Banzett, RB; Hallowell, RW; O'Donnell, CR; Schwartzstein, R; Sheridan, A, 2020) |
| "Aerosolized furosemide has been shown to relieve dyspnea; nevertheless, all published studies have shown great variability in response." | 9.27 | Aerosol furosemide for dyspnea: Controlled delivery does not improve effectiveness. ( Banzett, RB; Lansing, RW; Morélot-Panzini, C; O'Donnell, CR; Schwartzstein, RM, 2018) |
| "The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan database was examined to assess the short-term clinical course of patients hospitalized with heart failure and hyponatremia and the effect of tolvaptan on outcomes." | 9.17 | Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. ( Burnett, J; Gheorghiade, M; Grinfeld, L; Hauptman, PJ; Konstam, MA; Kostic, D; Krasa, HB; Maggioni, A; Ouyang, J; Swedberg, K; Udelson, JE; Zannad, F; Zimmer, C, 2013) |
| "Our findings do not support a beneficial effect from nebulised furosemide in patients with cancer related breathlessness." | 9.13 | Randomised, placebo controlled trial of nebulised furosemide for breathlessness in patients with cancer. ( Bell, S; Chauhan, A; El Khoury, B; Feathers, L; Frisby, J; Howard, P; Lewis, M; Manderson, C; Tattersfield, A; Walton, A; Wilcock, A, 2008) |
| "The aim of this study is to investigate the effects of inhaled furosemide on the sensation of dyspnea produced during exercise in patients with stable chronic obstructive pulmonary disease (COPD)." | 9.11 | Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease. ( Chong, WF; Earnest, A; Kor, AC; Ong, KC; Wang, YT, 2004) |
| "We evaluated the effect of ultrasonically nebulized furosemide (20 mg) on dyspnea uncontrollable by standard therapy in patients with terminal cancer." | 7.72 | Effect of nebulized furosemide in terminally ill cancer patients with dyspnea. ( Aoe, K; Kohara, H; Maeda, T; Saito, R; Shima, Y; Takeyama, H; Uchitomi, Y; Ueoka, H, 2003) |
| "Three terminal cancer patients with severe dyspnea were treated with nebulized furosemide." | 7.71 | Nebulized furosemide as a novel treatment for dyspnea in terminal cancer patients. ( Shimoyama, M; Shimoyama, N, 2002) |
| "Bronchiolitis is one of the most common disorders of the lower respiratory tract in infants." | 6.87 | A Randomized Controlled Trial of a Single Dose Furosemide to Improve Respiratory Distress in Moderate to Severe Bronchiolitis. ( Avarello, J; Bredin, G; Gangadharan, S; Williamson, K, 2018) |
| "Dyspnea is the hallmark symptom of some respiratory diseases such as chronic obstructive pulmonary disease and bronchiolitis and is a major reason for which these patients seek medical attention." | 6.73 | Furosemide inhalation in dyspnea of mustard gas-exposed patients: a triple-blind randomized study. ( Alaeddini, F; Aslani, J; Ghanei, M; Motiei-Langroudi, R; Naghizadeh, MM; Panahi, Y, 2008) |
| "Dyspnea is a common and distressing symptom associated with multiple chronic illnesses and high levels of burden for individuals, their families and health care systems." | 6.44 | Nebulized furosemide for the management of dyspnea: does the evidence support its use? ( Davidson, PM; Krum, H; Macdonald, P; Newton, PJ; Ollerton, R, 2008) |
| "To evaluate whether the addition of hydrochlorothiazide (HCTZ) to intravenous furosemide is a safe and effective strategy for improving diuretic response in acute heart failure (AHF)." | 5.69 | Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. ( Carrera-Izquierdo, M; Casado, J; Cerqueiro, JM; Conde-Martel, A; Dávila-Ramos, MF; Formiga, F; Gil, P; Llácer, P; Manzano, L; Morales-Rull, JL; Pérez-Silvestre, J; Plasín, MÁ; Salamanca-Bautista, P; Sánchez-Marteles, M; Trullàs, JC, 2023) |
| "Aerosol furosemide may be an option to treat refractory dyspnea, though doses, methods of delivery, and outcomes have been variable." | 5.34 | Controlled Delivery of 80 mg Aerosol Furosemide Does Not Achieve Consistent Dyspnea Relief in Patients. ( Banzett, RB; Hallowell, RW; O'Donnell, CR; Schwartzstein, R; Sheridan, A, 2020) |
| "Aerosolized furosemide has been shown to relieve dyspnea; nevertheless, all published studies have shown great variability in response." | 5.27 | Aerosol furosemide for dyspnea: Controlled delivery does not improve effectiveness. ( Banzett, RB; Lansing, RW; Morélot-Panzini, C; O'Donnell, CR; Schwartzstein, RM, 2018) |
| "We examined diuretic response (defined as Δ weight kg/40 mg furosemide) in 1745 hospitalized acute heart failure patients from the PROTECT trial." | 5.19 | Diuretic response in acute heart failure: clinical characteristics and prognostic significance. ( Bloomfield, DM; Cleland, JG; Cotter, G; Damman, K; Davison, B; Dittrich, HC; Fiuzat, M; Givertz, MM; Hillege, HL; Massie, BM; Metra, M; O'Connor, CM; Ponikowski, P; Teerlink, JR; Valente, MA; Van Veldhuisen, DJ; Voors, AA, 2014) |
| "The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan database was examined to assess the short-term clinical course of patients hospitalized with heart failure and hyponatremia and the effect of tolvaptan on outcomes." | 5.17 | Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. ( Burnett, J; Gheorghiade, M; Grinfeld, L; Hauptman, PJ; Konstam, MA; Kostic, D; Krasa, HB; Maggioni, A; Ouyang, J; Swedberg, K; Udelson, JE; Zannad, F; Zimmer, C, 2013) |
| "In a prospective, double-blind, randomized trial, we assigned 308 patients with acute decompensated heart failure to receive furosemide administered intravenously by means of either a bolus every 12 hours or continuous infusion and at either a low dose (equivalent to the patient's previous oral dose) or a high dose (2." | 5.15 | Diuretic strategies in patients with acute decompensated heart failure. ( Anstrom, KJ; Bart, BA; Braunwald, E; Bull, DA; Chen, HH; Deswal, A; Felker, GM; Givertz, MM; Goldsmith, SR; Hernandez, AF; Kfoury, AG; Lee, KL; LeWinter, MM; Mascette, AM; McNulty, SE; O'Connor, CM; Ofili, EO; Redfield, MM; Rouleau, JL; Semigran, MJ; Stevenson, LW; Velazquez, EJ, 2011) |
| "Our findings do not support a beneficial effect from nebulised furosemide in patients with cancer related breathlessness." | 5.13 | Randomised, placebo controlled trial of nebulised furosemide for breathlessness in patients with cancer. ( Bell, S; Chauhan, A; El Khoury, B; Feathers, L; Frisby, J; Howard, P; Lewis, M; Manderson, C; Tattersfield, A; Walton, A; Wilcock, A, 2008) |
| "The aim of this study is to investigate the effects of inhaled furosemide on the sensation of dyspnea produced during exercise in patients with stable chronic obstructive pulmonary disease (COPD)." | 5.11 | Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease. ( Chong, WF; Earnest, A; Kor, AC; Ong, KC; Wang, YT, 2004) |
| "We previously showed that inhaled furosemide improves experimentally induced dyspnea." | 5.10 | Effects of inhaled furosemide on CO(2) ventilatory responsiveness in humans. ( Ide, T; Minowa, Y; Nishino, T, 2002) |
| "Furosemide remains the drug of choice for patients with the transurethral resection syndrome." | 5.06 | Furosemide-induced disturbances of renal function in patients undergoing TURP. ( Deshon, GE; Donatucci, CF; Hunt, M; Wade, CE, 1990) |
| " Eight studies evaluated opioids in any route of administration, seven studies evaluated the use of oxygen, two studies assessed the role of benzodiazepines and two studies evaluated the role of furosemide in alleviating cancer-related dyspnea." | 4.88 | Interventions for alleviating cancer-related dyspnea: a systematic review and meta-analysis. ( Ben-Aharon, I; Gafter-Gvili, A; Leibovici, L; Stemmer, SM, 2012) |
| "Relief of congestion is a major objective of heart failure treatment but therapy remains based on the administration of furosemide, an agent that is often not effective and is associated with poor outcomes." | 4.87 | Can we improve the treatment of congestion in heart failure? ( Bettari, L; Bugatti, S; Carubelli, V; Cas, LD; Danesi, R; Lazzarini, V; Lombardi, C; Metra, M, 2011) |
| "The effective management of dyspnea in COPD remains a significant challenge for caregivers but recent treatment innovations such as helium-oxygen, inhaled furosemide and breathing feedback techniques have yielded early positive results." | 4.86 | Exertional dyspnea in chronic obstructive pulmonary disease: mechanisms and treatment approaches. ( Jensen, D; O'Donnell, DE; Ora, J, 2010) |
| " She was treated because of low left ventricular ejection fraction and impression of postpartum cardiomyopathy, and her severe dyspnea improved by intravenous furosemide." | 4.02 | Severe acute respiratory syndrome coronavirus-2- or pregnancy-related cardiomyopathy, a differential to be considered in the current pandemic: a case report. ( Hajizadeh, R; Kavandi, H; Khademolhosseini, S; Nejadrahim, R, 2021) |
| "We evaluated the effect of ultrasonically nebulized furosemide (20 mg) on dyspnea uncontrollable by standard therapy in patients with terminal cancer." | 3.72 | Effect of nebulized furosemide in terminally ill cancer patients with dyspnea. ( Aoe, K; Kohara, H; Maeda, T; Saito, R; Shima, Y; Takeyama, H; Uchitomi, Y; Ueoka, H, 2003) |
| "Three terminal cancer patients with severe dyspnea were treated with nebulized furosemide." | 3.71 | Nebulized furosemide as a novel treatment for dyspnea in terminal cancer patients. ( Shimoyama, M; Shimoyama, N, 2002) |
| "Thiamine deficiency as a cause for an elevated serum lactate or lactate acidosis with or without cardiovascular failure may not be overlooked." | 3.70 | [Unclear lactate acidosis in a patient with heart failure under long-term diuretic therapy]. ( Duell, T; Hiddemann, W; Mittermüller, J, 2000) |
| " After treatment of the cardiac failure with frusemide (up to 500 mg daily intravenously), nitrates and captopril (25 mg daily by mouth) the diagnosis was confirmed by transoesophageal echocardiography." | 3.69 | [Acute mitral insufficiency in osteogenesis imperfecta]. ( Borchard, F; Horstkotte, D; Kober, R; Königshausen, T; Krahwinkel, W; Strauer, BE; Winter, J, 1994) |
| "Bronchiolitis is one of the most common disorders of the lower respiratory tract in infants." | 2.87 | A Randomized Controlled Trial of a Single Dose Furosemide to Improve Respiratory Distress in Moderate to Severe Bronchiolitis. ( Avarello, J; Bredin, G; Gangadharan, S; Williamson, K, 2018) |
| "Dyspnea is the hallmark symptom of some respiratory diseases such as chronic obstructive pulmonary disease and bronchiolitis and is a major reason for which these patients seek medical attention." | 2.73 | Furosemide inhalation in dyspnea of mustard gas-exposed patients: a triple-blind randomized study. ( Alaeddini, F; Aslani, J; Ghanei, M; Motiei-Langroudi, R; Naghizadeh, MM; Panahi, Y, 2008) |
| "Chronic breathlessness is a troublesome symptom experienced by people with advanced malignant and nonmalignant disease." | 2.61 | Updates in opioid and nonopioid treatment for chronic breathlessness. ( Abdallah, SJ; Jensen, D; Lewthwaite, H, 2019) |
| "More research is needed to assess the characteristics of specific diseases and the combination of different nebulizers and medications that may yield the greatest benefit, and to assess the safety and efficacy of the chronic use of nebulized opioids and furosemide." | 2.52 | Nebulized medications for the treatment of dyspnea: a literature review. ( Boyden, JY; Connor, SR; Davis, MS; Fine, PG; Muir, JC; Nathan, SD; Otolorin, L, 2015) |
| "Dyspnea in chronic obstructive pulmonary disease is clearly related to hyperinflation, and lung volumes are valuable for characterizing disease." | 2.44 | Mechanisms of dyspnea in chronic lung disease. ( Rock, LK; Schwartzstein, RM, 2007) |
| " Optimal dosing of opioids is being refined." | 2.44 | Pharmacological management of dyspnoea. ( Abernethy, AP; Currow, DC, 2007) |
| "Dyspnea is a common and distressing symptom associated with multiple chronic illnesses and high levels of burden for individuals, their families and health care systems." | 2.44 | Nebulized furosemide for the management of dyspnea: does the evidence support its use? ( Davidson, PM; Krum, H; Macdonald, P; Newton, PJ; Ollerton, R, 2008) |
| "Chest pain and shortness of breath are chief complaints frequently evaluated in the emergency department." | 1.48 | An uncommon cause of dyspnea in the emergency department. ( Kotora, JG; Schmieler, EJ; St Clair, JW, 2018) |
| "Swimming Induced Pulmonary Edema, or SIPE, is an emerging condition occurring in otherwise healthy individuals during surface swimming or diving that is characterized by cough, dyspnea, hemoptysis, and hypoxemia." | 1.46 | Swimming-induced pulmonary oedema an uncommon condition diagnosed with POCUS ultrasound. ( Alonso, JV; Borakati, R; Chowdhury, M; Gankande, U, 2017) |
| "Thyroid storm (also known as thyroid or thyrotoxic crisis) is part of the spectrum of thyrotoxicosis and represents the extreme end of that spectrum." | 1.46 | Iodinated Contrast Administration Resulting in Cardiogenic Shock in Patient with Uncontrolled Graves Disease. ( Brundridge, W; Perkins, J, 2017) |
| "We report a woman with myelofibrosis and myeloid metaplasia who presented with dyspnea and massive, painful splenomegaly." | 1.35 | [Dyspnea secondary to pulmonary hypertension in a patient with splenic myeloid metaplasia]. ( Anouti, S; Haddad, F; Jammal, M; Kettaneh, A; Maalouly, G; Nemnoum, R, 2009) |
| "We describe a case of severe congestive heart failure and right ventricular overload associated with overt hyperthyroidism, completely reversed with antithyroid therapy in a few week." | 1.35 | Hyperthyroidism as a reversible cause of right ventricular overload and congestive heart failure. ( Di Giovambattista, R, 2008) |
| "Instrumental examinations revealed congestive heart failure and multiple focal lesions in the liver with typical features of hemangiomas." | 1.32 | Recombinant interferon alfa 2a in hepatic hemangiomatosis with congestive heart failure: a case report. ( Clerico, A; De Pasquale, MD; Di Salvo, S; Schiavetti, A; Ventriglia, F, 2003) |
| "All these findings indicated restrictive cardiomyopathy as part of primary systemic amyloidosis." | 1.29 | [Primary systemic amyloidosis with cardiac manifestations]. ( Fischer, H; Morell, R; Woitinas, F; Zwehl, W, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (7.06) | 18.7374 |
| 1990's | 10 (11.76) | 18.2507 |
| 2000's | 27 (31.76) | 29.6817 |
| 2010's | 36 (42.35) | 24.3611 |
| 2020's | 6 (7.06) | 2.80 |
| Authors | Studies |
|---|---|
| Duvvuri, PD | 1 |
| Bhardwaj, C | 1 |
| Wattanakit, K | 1 |
| Trullàs, JC | 3 |
| Morales-Rull, JL | 3 |
| Casado, J | 3 |
| Carrera-Izquierdo, M | 3 |
| Sánchez-Marteles, M | 3 |
| Conde-Martel, A | 3 |
| Dávila-Ramos, MF | 3 |
| Llácer, P | 3 |
| Salamanca-Bautista, P | 3 |
| Pérez-Silvestre, J | 3 |
| Plasín, MÁ | 3 |
| Cerqueiro, JM | 3 |
| Gil, P | 3 |
| Formiga, F | 3 |
| Manzano, L | 3 |
| Rohde, LE | 1 |
| Rover, MM | 1 |
| Figueiredo Neto, JA | 1 |
| Danzmann, LC | 1 |
| Bertoldi, EG | 1 |
| Simões, MV | 1 |
| Silvestre, OM | 1 |
| Ribeiro, ALP | 1 |
| Moura, LZ | 1 |
| Beck-da-Silva, L | 1 |
| Prado, D | 1 |
| Sant'Anna, RT | 1 |
| Bridi, LH | 1 |
| Zimerman, A | 1 |
| Raupp da Rosa, P | 1 |
| Biolo, A | 1 |
| Hallowell, RW | 1 |
| Schwartzstein, R | 1 |
| O'Donnell, CR | 3 |
| Sheridan, A | 1 |
| Banzett, RB | 4 |
| McVeigh, T | 1 |
| Moore, C | 1 |
| Syed, MP | 1 |
| Doshi, A | 1 |
| Pandey, D | 1 |
| Kate, Y | 1 |
| Harizi, R | 1 |
| Nejadrahim, R | 1 |
| Khademolhosseini, S | 1 |
| Kavandi, H | 1 |
| Hajizadeh, R | 1 |
| Schwartzstein, RM | 4 |
| Lansing, RW | 3 |
| Alonso, JV | 1 |
| Chowdhury, M | 1 |
| Borakati, R | 1 |
| Gankande, U | 1 |
| Morélot-Panzini, C | 1 |
| Brundridge, W | 1 |
| Perkins, J | 1 |
| Williamson, K | 1 |
| Bredin, G | 1 |
| Avarello, J | 1 |
| Gangadharan, S | 1 |
| Schmieler, EJ | 1 |
| St Clair, JW | 1 |
| Kotora, JG | 1 |
| Clark, JE | 1 |
| de la Fuente, J | 1 |
| Hafdahl, LT | 1 |
| Bhargava, R | 1 |
| Cowell, R | 1 |
| Abdallah, SJ | 1 |
| Jensen, D | 3 |
| Lewthwaite, H | 1 |
| Mauer, AC | 1 |
| Baron, SJ | 1 |
| Yeh, RW | 1 |
| Scott, NS | 1 |
| Windsor, R | 1 |
| Petchey, W | 1 |
| Hauptman, PJ | 1 |
| Burnett, J | 1 |
| Gheorghiade, M | 1 |
| Grinfeld, L | 1 |
| Konstam, MA | 1 |
| Kostic, D | 1 |
| Krasa, HB | 1 |
| Maggioni, A | 1 |
| Ouyang, J | 1 |
| Swedberg, K | 1 |
| Zannad, F | 1 |
| Zimmer, C | 1 |
| Udelson, JE | 1 |
| Valente, MA | 1 |
| Voors, AA | 1 |
| Damman, K | 1 |
| Van Veldhuisen, DJ | 1 |
| Massie, BM | 1 |
| O'Connor, CM | 3 |
| Metra, M | 2 |
| Ponikowski, P | 1 |
| Teerlink, JR | 1 |
| Cotter, G | 1 |
| Davison, B | 1 |
| Cleland, JG | 1 |
| Givertz, MM | 2 |
| Bloomfield, DM | 1 |
| Fiuzat, M | 1 |
| Dittrich, HC | 1 |
| Hillege, HL | 1 |
| Boyden, JY | 1 |
| Connor, SR | 1 |
| Otolorin, L | 1 |
| Nathan, SD | 1 |
| Fine, PG | 1 |
| Davis, MS | 1 |
| Muir, JC | 1 |
| Yelve, K | 1 |
| Panandikar, GA | 1 |
| Pazare, A | 1 |
| Bajpai, S | 1 |
| Laster, M | 1 |
| Im, D | 1 |
| Ahn, A | 1 |
| Ho, CH | 1 |
| Awan, S | 1 |
| Wilcock, A | 2 |
| Wen, S | 1 |
| Ning, J | 1 |
| Collins, S | 1 |
| Berry, D | 1 |
| Di Giovambattista, R | 1 |
| Panahi, Y | 1 |
| Motiei-Langroudi, R | 1 |
| Alaeddini, F | 1 |
| Naghizadeh, MM | 1 |
| Aslani, J | 1 |
| Ghanei, M | 1 |
| Currow, DC | 2 |
| Abernethy, AP | 2 |
| Rock, LK | 1 |
| Nishino, T | 3 |
| Ward, AM | 1 |
| Haddad, F | 1 |
| Anouti, S | 1 |
| Maalouly, G | 1 |
| Jammal, M | 1 |
| Nemnoum, R | 1 |
| Kettaneh, A | 1 |
| Parker, T | 1 |
| Ora, J | 1 |
| O'Donnell, DE | 2 |
| Towers, KA | 1 |
| Bardsley, KA | 1 |
| Macdonald, PS | 1 |
| Holzer-Richling, N | 1 |
| Holzer, M | 1 |
| Herkner, H | 1 |
| Riedmüller, E | 1 |
| Havel, C | 1 |
| Kaff, A | 1 |
| Malzer, R | 1 |
| Schreiber, W | 1 |
| Bugatti, S | 1 |
| Bettari, L | 1 |
| Carubelli, V | 1 |
| Danesi, R | 1 |
| Lazzarini, V | 1 |
| Lombardi, C | 1 |
| Cas, LD | 1 |
| Felker, GM | 2 |
| Lee, KL | 2 |
| Bull, DA | 1 |
| Redfield, MM | 2 |
| Stevenson, LW | 1 |
| Goldsmith, SR | 1 |
| LeWinter, MM | 1 |
| Deswal, A | 1 |
| Rouleau, JL | 1 |
| Ofili, EO | 1 |
| Anstrom, KJ | 1 |
| Hernandez, AF | 2 |
| McNulty, SE | 2 |
| Velazquez, EJ | 1 |
| Kfoury, AG | 1 |
| Chen, HH | 1 |
| Semigran, MJ | 1 |
| Bart, BA | 1 |
| Mascette, AM | 1 |
| Braunwald, E | 2 |
| Dalzell, JR | 1 |
| Wada, Y | 1 |
| Kobayashi, D | 1 |
| Murakami, S | 1 |
| Oda, M | 1 |
| Hanawa, H | 1 |
| Kuroda, T | 1 |
| Nakano, M | 1 |
| Narita, I | 1 |
| Lum, E | 1 |
| Tymchuk, C | 1 |
| Serag, R | 1 |
| Afsarmanesh, N | 1 |
| Clark, SL | 1 |
| Hankins, GD | 1 |
| Shochat, M | 1 |
| Shotan, A | 1 |
| Blondheim, DS | 1 |
| Kazatsker, M | 1 |
| Dahan, I | 1 |
| Asif, A | 1 |
| Shochat, I | 1 |
| Rabinovich, P | 1 |
| Rozenman, Y | 1 |
| Meisel, SR | 1 |
| Banerjee, P | 1 |
| Tanner, G | 1 |
| Williams, L | 1 |
| Abudiab, MM | 1 |
| Odunukan, OW | 1 |
| Freeman, WK | 1 |
| Carrascosa, MF | 1 |
| Larroque, IC | 1 |
| Rivero, JL | 1 |
| García, JA | 1 |
| Hoz, MC | 1 |
| Ares, MA | 1 |
| López, XA | 1 |
| Caviedes, JR | 1 |
| Ben-Aharon, I | 1 |
| Gafter-Gvili, A | 1 |
| Leibovici, L | 1 |
| Stemmer, SM | 1 |
| Kociol, RD | 1 |
| Tracy, RP | 1 |
| Koslow, M | 1 |
| Raskin, S | 1 |
| Sidi, Y | 1 |
| Ben-Dov, I | 1 |
| Segel, MJ | 1 |
| Minowa, Y | 1 |
| Ide, T | 2 |
| Stone, P | 2 |
| Kurowska, A | 2 |
| Schiavetti, A | 1 |
| De Pasquale, MD | 1 |
| Di Salvo, S | 1 |
| Ventriglia, F | 1 |
| Clerico, A | 1 |
| Gouin, S | 1 |
| Ali, S | 1 |
| MONTUSCHI, E | 1 |
| Kohara, H | 1 |
| Ueoka, H | 1 |
| Aoe, K | 1 |
| Maeda, T | 1 |
| Takeyama, H | 1 |
| Saito, R | 1 |
| Shima, Y | 1 |
| Uchitomi, Y | 1 |
| Ong, KC | 1 |
| Kor, AC | 1 |
| Chong, WF | 1 |
| Earnest, A | 1 |
| Wang, YT | 1 |
| Tran, HA | 1 |
| Moosavi, SH | 1 |
| Binks, AP | 1 |
| Topulos, GP | 1 |
| Lewis, E | 1 |
| Stacey, MR | 1 |
| Deady, B | 1 |
| Glezo, J | 1 |
| Blackie, S | 1 |
| Kallet, RH | 1 |
| Amjadi, K | 1 |
| Harris-McAllister, V | 1 |
| Webb, KA | 1 |
| Walton, A | 1 |
| Manderson, C | 1 |
| Feathers, L | 1 |
| El Khoury, B | 1 |
| Lewis, M | 1 |
| Chauhan, A | 1 |
| Howard, P | 1 |
| Bell, S | 1 |
| Frisby, J | 1 |
| Tattersfield, A | 1 |
| Cachia, E | 1 |
| Ahmedzai, SH | 1 |
| Newton, PJ | 1 |
| Davidson, PM | 1 |
| Macdonald, P | 1 |
| Ollerton, R | 1 |
| Krum, H | 1 |
| Fischer, H | 1 |
| Woitinas, F | 1 |
| Morell, R | 1 |
| Zwehl, W | 1 |
| Subratty, AH | 1 |
| Manraj, M | 1 |
| Baligadoo, S | 1 |
| Tookman, A | 1 |
| Krahwinkel, W | 1 |
| Kober, R | 1 |
| Horstkotte, D | 1 |
| Borchard, F | 1 |
| Winter, J | 1 |
| Strauer, BE | 1 |
| Königshausen, T | 1 |
| Sandstede, J | 1 |
| Hopf, R | 1 |
| Härisch, B | 1 |
| Becker, EW | 1 |
| Gavaghan, BJ | 1 |
| Kittleson, MD | 1 |
| Herfel, R | 1 |
| Stone, CK | 1 |
| Koury, SI | 1 |
| Blake, JJ | 1 |
| Nakagawa, C | 1 |
| Sakaguchi, Y | 1 |
| Nakajima, T | 1 |
| Kawamoto, A | 1 |
| Uemura, S | 1 |
| Fujimoto, S | 1 |
| Hashimoto, T | 1 |
| Dohi, K | 1 |
| Shirai, T | 1 |
| Rutgers, SR | 1 |
| Schweitzer, M | 1 |
| Sudo, T | 1 |
| Sato, J | 1 |
| Duell, T | 1 |
| Mittermüller, J | 1 |
| Hiddemann, W | 1 |
| Shinohara, T | 1 |
| Yanai, H | 1 |
| Hidaka, T | 1 |
| Suzuki, K | 1 |
| Ohsuzu, F | 1 |
| Shimoyama, N | 1 |
| Shimoyama, M | 1 |
| Müting, D | 1 |
| Donatucci, CF | 1 |
| Deshon, GE | 1 |
| Wade, CE | 1 |
| Hunt, M | 1 |
| Michailov, ML | 1 |
| Kunov, A | 1 |
| Amjad, H | 1 |
| Bigman, O | 1 |
| Tabor, H | 1 |
| Llamas, R | 1 |
| Forthman, HJ | 1 |
| Marin, Iv | 1 |
| Grigorov, Ml | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety and Tolerability of Diuretics Withdrawal in Heart Failure With Reduced Ejection Fraction. REDICAE Trial.[NCT05964738] | Phase 2 | 90 participants (Anticipated) | Interventional | 2022-12-19 | Recruiting | ||
| Effect of Furosemide Withdraw in Stable Chronic Heart Failure Outpatients With Left Ventricular Dysfunction - the Brazilian Research Network on Heart Failure[NCT02689180] | Phase 3 | 230 participants (Anticipated) | Interventional | 2015-05-31 | Recruiting | ||
| Single Dose of Furosemide to Improve Respiratory Distress in Moderate to Severe Bronchiolitis[NCT02469597] | Phase 2 | 46 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Protocol 156-03-236: Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized With Worsening Congestive Heart Failure[NCT00071331] | Phase 3 | 3,600 participants | Interventional | 2003-09-30 | Completed | ||
| A Randomized, Open-label Study of Dapagliflozin in Patients With or Without Type 2 Diabetes Admitted With Acute Heart Failure[NCT04298229] | Phase 3 | 240 participants (Actual) | Interventional | 2020-04-01 | Completed | ||
| Nebulized Fentanyl for Respiratory Symptoms in Patients With COVID-19 (Ventanyl Trial)[NCT05165992] | Phase 3 | 200 participants (Anticipated) | Interventional | 2022-02-28 | Not yet recruiting | ||
| Continuous Versus Intermittent Loop Diuretics Infusion Dosing in Acute Heart Failure: Effects on Renal Function, Outcome and BNP Levels[NCT01441245] | Phase 4 | 57 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)[NCT00577135] | Phase 3 | 308 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Continuous Versus Bolus Intermittent Loop Diuretic Infusion in Acutely Decompensated Heart Failure: Evaluation of Renal Function, Congestion Signs, BNP and Outcome[NCT02638142] | 116 participants (Actual) | Observational | 2015-12-31 | Active, not recruiting | |||
| Efficacy and Tolerability of Combination Intravenous Diuretic Therapy Versus Intravenous Loop Diuretic Therapy Alone for the Treatment of Acute Decompensated Heart Failure[NCT05840536] | Phase 4 | 0 participants (Actual) | Interventional | 2014-05-31 | Withdrawn | ||
| High-Dose Aldactone for Treatment of Diuretic Resistant Heart Failure[NCT02429388] | Phase 4 | 0 participants (Actual) | Interventional | 2014-05-31 | Withdrawn (stopped due to Principal Investigator left institution prior to subjects being enrolled) | ||
| Remote Dielectric Sensing (ReDS) for a SAFE Discharge in Patients With Acutely Decompensated Heart Failure: The ReDS-SAFE HF Study[NCT04305717] | 240 participants (Anticipated) | Interventional | 2020-08-14 | Recruiting | |||
| Specificity of Dyspnoea Relief With Inhaled Furosemide[NCT02881866] | Phase 1 | 16 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02469597)
Timeframe: Participants will be followed for the duration of hospital stay up to 1 week
| Intervention | Days (Least Squares Mean) |
|---|---|
| Single Dose of Furosemide | 3.1 |
| Placebo | 3.0 |
(NCT02469597)
Timeframe: 2 hours after medication adminstration
| Intervention | Percentage change in oxygen saturation (Least Squares Mean) |
|---|---|
| Single Dose of Furosemide | -0.14 |
| Placebo | 0.2 |
(NCT02469597)
Timeframe: 4 hours after medication adminstration
| Intervention | Percentage change in oxygen saturation (Least Squares Mean) |
|---|---|
| Single Dose of Furosemide | -0.19 |
| Placebo | 0.29 |
(NCT02469597)
Timeframe: Within 72 hours of medication administration
| Intervention | participants (Number) |
|---|---|
| Single Dose of Furosemide | 0 |
| Placebo | 0 |
(NCT02469597)
Timeframe: 2 hours after medication adminstration
| Intervention | Percentage change in respiratory rate (Least Squares Mean) |
|---|---|
| Single Dose of Furosemide | -3.7 |
| Placebo | -1.7 |
(NCT02469597)
Timeframe: 4 hours after medication adminstration
| Intervention | Percentage change in respiratory rate (Least Squares Mean) |
|---|---|
| Single Dose of Furosemide | -2.8 |
| Placebo | -5.4 |
(NCT01441245)
Timeframe: participants were followed for the duration of hospital stay, an average of 13 days
| Intervention | pg/mL (Mean) |
|---|---|
| BNP Change in cIV | -525 |
| BNP Change in iIV | -148 |
(NCT01441245)
Timeframe: in-hospital
| Intervention | percentage of partecipants (Number) |
|---|---|
| Dopamine Infusion in cIV | 50 |
| Dopamine Infusion in iIV | 26 |
(NCT01441245)
Timeframe: from admission to discharge, an average of 12 days
| Intervention | pg/ml (Mean) |
|---|---|
| BNP Levels at Discharge in cIV Group | 679 |
| BNP Levels at Discharge in iIV Group | 949 |
this study aimed to evaluate the effects of continuous infusion of furosemide in comparison to twice daily regimens at similar doses with respect to changes in renal function in terms of creatinine levels and GFR, urine output and BNP levels from admission to discharge (NCT01441245)
Timeframe: time period ranging from 72 h to 120 h.
| Intervention | mL (Mean) |
|---|---|
| Urine Output in cIV | 2505 |
| Urine Output in iIV | 2140 |
evaluation of renal function in terms of changes in creatinine levels during hospitalization in the two arms. (NCT01441245)
Timeframe: participants were followed for the duration of hospital stay, an average of 13 days
| Intervention | mg/dL (Mean) |
|---|---|
| Changes in Creatinine in cIV Group | -0.10 |
| Changes in Creatinine in iIV Group | -0.50 |
(NCT01441245)
Timeframe: from admission to discharge, an average of 12 days
| Intervention | (ml/min·1.73 m2) (Mean) |
|---|---|
| GFR Change in cIV | -3.18 |
| GFR Change in iIV | -1.93 |
(NCT01441245)
Timeframe: from admission to discharge, an average of 12 days
| Intervention | mg/dL (Mean) |
|---|---|
| Creatinine at Discharge in cIV | 1.78 |
| Creatinine at Discharge in iIV | 1.51 |
(NCT01441245)
Timeframe: from admission to discharge, an average of 12 days
| Intervention | (ml/min·1.73 m2) (Mean) |
|---|---|
| GFR at Discharge in cIV | 44.8 |
| GFR at Discharge in iIV | 46.7 |
percentage of participants with hospital stay > 10 days (NCT01441245)
Timeframe: in-hospital
| Intervention | percentage of partecipants (Number) |
|---|---|
| Lenght of Hospitalization in cIV | 80 |
| Lenght of Hospitalization in iIV | 44 |
Change in NTproBNP (NCT00577135)
Timeframe: baseline and 72 hours
| Intervention | pg/mL (Mean) |
|---|---|
| Q 12 Hour Bolus | -1316.2 |
| Continuous Infusion | -1773.2 |
| Low Intensification | -1193.8 |
| High Intensification | -1881.6 |
(NCT00577135)
Timeframe: baseline and 72 hours
| Intervention | mg/L (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.11 |
| Continuous Infusion | 0.17 |
| Low Intensification | 0.12 |
| High Intensification | 0.17 |
(NCT00577135)
Timeframe: baseline and day 60
| Intervention | mg/L (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.20 |
| Continuous Infusion | 0.16 |
| Low Intensification | 0.18 |
| High Intensification | 0.18 |
(NCT00577135)
Timeframe: baseline and day 7
| Intervention | mg/L (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.21 |
| Continuous Infusion | 0.16 |
| Low Intensification | 0.16 |
| High Intensification | 0.21 |
(NCT00577135)
Timeframe: baseline and Day 60
| Intervention | pg/mL (Mean) |
|---|---|
| Q 12 Hour Bolus | -1449.3 |
| Continuous Infusion | -1035.1 |
| Low Intensification | -1445.6 |
| High Intensification | -1038.5 |
(NCT00577135)
Timeframe: baseline and Day 7
| Intervention | pg/mL (Mean) |
|---|---|
| Q 12 Hour Bolus | -1133.3 |
| Continuous Infusion | -1552.0 |
| Low Intensification | -1037.2 |
| High Intensification | -1629.7 |
(NCT00577135)
Timeframe: baseline and 24 hours
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.00 |
| Continuous Infusion | 0.01 |
| Low Intensification | -0.01 |
| High Intensification | 0.02 |
(NCT00577135)
Timeframe: baseline and 48 hours
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.02 |
| Continuous Infusion | 0.05 |
| Low Intensification | 0.01 |
| High Intensification | 0.06 |
(NCT00577135)
Timeframe: baseline and 96 hours
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.06 |
| Continuous Infusion | 0.05 |
| Low Intensification | 0.05 |
| High Intensification | 0.07 |
(NCT00577135)
Timeframe: baseline and day 60
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.09 |
| Continuous Infusion | 0.07 |
| Low Intensification | 0.09 |
| High Intensification | 0.07 |
(NCT00577135)
Timeframe: baseline and day 7
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.10 |
| Continuous Infusion | 0.04 |
| Low Intensification | 0.07 |
| High Intensification | 0.08 |
(NCT00577135)
Timeframe: Measured at baseline and 72 hours
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.05 |
| Continuous Infusion | 0.07 |
| Low Intensification | 0.04 |
| High Intensification | 0.08 |
(NCT00577135)
Timeframe: baseline and 72 hours
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.30 |
| Continuous Infusion | 0.44 |
| Low Intensification | 0.11 |
| High Intensification | 0.61 |
(NCT00577135)
Timeframe: baseline and Day 60
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | -0.09 |
| Continuous Infusion | -0.71 |
| Low Intensification | -0.13 |
| High Intensification | -0.67 |
(NCT00577135)
Timeframe: baseline and day 7
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.40 |
| Continuous Infusion | 0.09 |
| Low Intensification | 0.07 |
| High Intensification | 0.42 |
(NCT00577135)
Timeframe: baseline and 96 hours
| Intervention | lbs (Mean) |
|---|---|
| Q 12 Hour Bolus | -8.0 |
| Continuous Infusion | -9.1 |
| Low Intensification | -7.4 |
| High Intensification | -9.6 |
Dyspnea Visual Analog Scale Scale Range 0-4800; higher score is better (NCT00577135)
Timeframe: 48 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Q 12 Hour Bolus | 2876.6 |
| Continuous Infusion | 3033.1 |
| Low Intensification | 2924.9 |
| High Intensification | 2981.3 |
Dyspnea Visual Analog Scale Scale Range 0-7200; higher score is better (NCT00577135)
Timeframe: 72 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Q 12 Hour Bolus | 4455.6 |
| Continuous Infusion | 4699.1 |
| Low Intensification | 4477.9 |
| High Intensification | 4668.3 |
Global Visual Analog Scale Scale Range 0-2400; higher score is better (NCT00577135)
Timeframe: Measured at 24 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Q 12 Hour Bolus | 1370.8 |
| Continuous Infusion | 1453.8 |
| Low Intensification | 1426.0 |
| High Intensification | 1398.2 |
(NCT00577135)
Timeframe: Through 24 hours
| Intervention | mL (Mean) |
|---|---|
| Q 12 Hour Bolus | 1595.7 |
| Continuous Infusion | 1796.4 |
| Low Intensification | 1209.7 |
| High Intensification | 2149.6 |
(NCT00577135)
Timeframe: Through 48 hours
| Intervention | mL (Mean) |
|---|---|
| Q 12 Hour Bolus | 2996.7 |
| Continuous Infusion | 3120.6 |
| Low Intensification | 2334.8 |
| High Intensification | 3747.4 |
(NCT00577135)
Timeframe: Through 72 hours
| Intervention | mL (Mean) |
|---|---|
| Q 12 Hour Bolus | 4236.7 |
| Continuous Infusion | 4249.2 |
| Low Intensification | 3575.2 |
| High Intensification | 4898.9 |
Global Visual Analog Scale Scale Range 0-2400; higher score is better (NCT00577135)
Timeframe: Measured at 24 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Q 12 Hour Bolus | 1280.8 |
| Continuous Infusion | 1303.0 |
| Low Intensification | 1288.6 |
| High Intensification | 1294.8 |
Global Visual Analog Scale Scale Range 0-4800; higher score is better (NCT00577135)
Timeframe: 48 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Q 12 Hour Bolus | 2722.6 |
| Continuous Infusion | 2792.6 |
| Low Intensification | 2706.5 |
| High Intensification | 2805.2 |
Global Visual Analog Scale Scale Range 0-7200; higher score is better (NCT00577135)
Timeframe: Measured at 72 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Q 12 Hour Bolus | 4236 |
| Continuous Infusion | 4372.7 |
| Low Intensification | 4170.8 |
| High Intensification | 4429.6 |
(NCT00577135)
Timeframe: Within 72 hours
| Intervention | percentage of participants (Number) |
|---|---|
| Q 12 Hour Bolus | 17.4 |
| Continuous Infusion | 19.2 |
| Low Intensification | 13.6 |
| High Intensification | 22.7 |
(NCT00577135)
Timeframe: Measured at 72 hours
| Intervention | percentage of participants (Number) |
|---|---|
| Q 12 Hour Bolus | 14.4 |
| Continuous Infusion | 15.3 |
| Low Intensification | 11.2 |
| High Intensification | 18.2 |
Treatment failure is defined as the patient met cardiorenal syndrome endpoint, worsening or persistent heart failure endpoint, patient died, or there was clinical evidence of overdiuresis requiring intervention within first 72 hours after randomization (NCT00577135)
Timeframe: Within 72 hours
| Intervention | percentage of participants (Number) |
|---|---|
| Q 12 Hour Bolus | 38.1 |
| Continuous Infusion | 38.8 |
| Low Intensification | 36.7 |
| High Intensification | 40.0 |
14 reviews available for furosemide and Dyspnea
| Article | Year |
|---|---|
Updates in opioid and nonopioid treatment for chronic breathlessness.
Topics: Analgesics, Opioid; Anti-Anxiety Agents; Breathing Exercises; Chronic Disease; Dose-Response Relatio | 2019 |
Nebulized medications for the treatment of dyspnea: a literature review.
Topics: Administration, Inhalation; Aerosols; Analgesics, Opioid; Dyspnea; Furosemide; Humans; Lung; Nebuliz | 2015 |
Nonopioid medication for the relief of refractory breathlessness.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Cannabinoids; Clinical Trials as Topic; Dyspnea; Furosem | 2015 |
Pharmacological management of dyspnoea.
Topics: Analgesics, Opioid; Benzodiazepines; Drug Administration Routes; Dyspnea; Forced Expiratory Volume; | 2007 |
Mechanisms of dyspnea in chronic lung disease.
Topics: Clinical Trials as Topic; Dyspnea; Exercise Tolerance; Furosemide; Humans; Pulmonary Disease, Chroni | 2007 |
Pathophysiology of dyspnea evaluated by breath-holding test: studies of furosemide treatment.
Topics: Animals; Dyspnea; Furosemide; Humans; Respiration; Sensation; Sodium Potassium Chloride Symporter In | 2009 |
Advances in the pharmacological management of breathlessness.
Topics: Dyspnea; Furosemide; Humans; Morphine; Narcotics; Nebulizers and Vaporizers; Palliative Care; Sodium | 2009 |
Exertional dyspnea in chronic obstructive pulmonary disease: mechanisms and treatment approaches.
Topics: Analgesics, Opioid; Dyspnea; Feedback, Physiological; Furosemide; Humans; Physical Exertion; Pulmona | 2010 |
Can we improve the treatment of congestion in heart failure?
Topics: Animals; Diuretics; Dyspnea; Edema; Furosemide; Heart Failure; Humans; Lung | 2011 |
Acute heart failure with dyspnoea: initial treatment. Furosemide and trinitrine, despite the lack of a proven survival benefit.
Topics: Acute Disease; Blood Pressure; Diuretics; Dyspnea; Furosemide; Heart Failure; Nitroglycerin; Vasodil | 2011 |
Interventions for alleviating cancer-related dyspnea: a systematic review and meta-analysis.
Topics: Analgesics, Opioid; Benzodiazepines; Dyspnea; Furosemide; Humans; Neoplasms; Oxygen; Palliative Care | 2012 |
The role of inhaled opioids and furosemide for the treatment of dyspnea.
Topics: Administration, Inhalation; Analgesics, Opioid; Dyspnea; Female; Furosemide; Humans; Male; Palliativ | 2007 |
Nebulized furosemide for the management of dyspnea: does the evidence support its use?
Topics: Administration, Inhalation; Clinical Trials as Topic; Dyspnea; Evidence-Based Medicine; Furosemide; | 2008 |
[Pathophysiology and therapy of altitude sickness].
Topics: Adolescent; Adult; Altitude Sickness; Cell Membrane Permeability; Dietary Carbohydrates; Diphosphogl | 1978 |
20 trials available for furosemide and Dyspnea
| Article | Year |
|---|---|
Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial.
Topics: Diuretics; Dyspnea; Female; Furosemide; Heart Failure; Humans; Hydrochlorothiazide; Hypokalemia; Pro | 2023 |
Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial.
Topics: Diuretics; Dyspnea; Female; Furosemide; Heart Failure; Humans; Hydrochlorothiazide; Hypokalemia; Pro | 2023 |
Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial.
Topics: Diuretics; Dyspnea; Female; Furosemide; Heart Failure; Humans; Hydrochlorothiazide; Hypokalemia; Pro | 2023 |
Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial.
Topics: Diuretics; Dyspnea; Female; Furosemide; Heart Failure; Humans; Hydrochlorothiazide; Hypokalemia; Pro | 2023 |
Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial.
Topics: Diuretics; Dyspnea; Female; Furosemide; Heart Failure; Humans; Hydrochlorothiazide; Hypokalemia; Pro | 2023 |
Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial.
Topics: Diuretics; Dyspnea; Female; Furosemide; Heart Failure; Humans; Hydrochlorothiazide; Hypokalemia; Pro | 2023 |
Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial.
Topics: Diuretics; Dyspnea; Female; Furosemide; Heart Failure; Humans; Hydrochlorothiazide; Hypokalemia; Pro | 2023 |
Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial.
Topics: Diuretics; Dyspnea; Female; Furosemide; Heart Failure; Humans; Hydrochlorothiazide; Hypokalemia; Pro | 2023 |
Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial.
Topics: Diuretics; Dyspnea; Female; Furosemide; Heart Failure; Humans; Hydrochlorothiazide; Hypokalemia; Pro | 2023 |
Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial.
Topics: Aged; Body Fluids; Brazil; Case-Control Studies; Double-Blind Method; Dyspnea; Female; Follow-Up Stu | 2019 |
Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial.
Topics: Aged; Body Fluids; Brazil; Case-Control Studies; Double-Blind Method; Dyspnea; Female; Follow-Up Stu | 2019 |
Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial.
Topics: Aged; Body Fluids; Brazil; Case-Control Studies; Double-Blind Method; Dyspnea; Female; Follow-Up Stu | 2019 |
Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial.
Topics: Aged; Body Fluids; Brazil; Case-Control Studies; Double-Blind Method; Dyspnea; Female; Follow-Up Stu | 2019 |
Controlled Delivery of 80 mg Aerosol Furosemide Does Not Achieve Consistent Dyspnea Relief in Patients.
Topics: Administration, Inhalation; Adult; Aerosols; Aged; Aged, 80 and over; Asthma; Chronic Disease; Cross | 2020 |
Aerosol furosemide for dyspnea: Controlled delivery does not improve effectiveness.
Topics: Administration, Inhalation; Aerosols; Cross-Over Studies; Double-Blind Method; Dyspnea; Female; Furo | 2018 |
A Randomized Controlled Trial of a Single Dose Furosemide to Improve Respiratory Distress in Moderate to Severe Bronchiolitis.
Topics: Bronchiolitis; Double-Blind Method; Dyspnea; Emergency Service, Hospital; Female; Furosemide; Humans | 2018 |
Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.
Topics: Aged; Analysis of Variance; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzaze | 2013 |
Diuretic response in acute heart failure: clinical characteristics and prognostic significance.
Topics: Acute Disease; Aged; Analysis of Variance; Atherosclerosis; Bumetanide; Diabetes Complications; Diur | 2014 |
A response-adaptive design of initial therapy for emergency department patients with heart failure.
Topics: Acute Disease; Bayes Theorem; Blood Pressure; Diuretics; Dyspnea; Emergency Service, Hospital; Furos | 2017 |
Furosemide inhalation in dyspnea of mustard gas-exposed patients: a triple-blind randomized study.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Chemical Warfare Agents; Cross-Over Stud | 2008 |
Randomized placebo controlled trial of furosemide on subjective perception of dyspnoea in patients with pulmonary oedema because of hypertensive crisis.
Topics: Aged; Aged, 80 and over; Diuretics; Double-Blind Method; Dyspnea; Female; Furosemide; Humans; Hypert | 2011 |
Diuretic strategies in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Area Under Curve; Creatinine; Diuretics; Double-Blind Method; Drug Administrati | 2011 |
Diuretic strategies in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Area Under Curve; Creatinine; Diuretics; Double-Blind Method; Drug Administrati | 2011 |
Diuretic strategies in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Area Under Curve; Creatinine; Diuretics; Double-Blind Method; Drug Administrati | 2011 |
Diuretic strategies in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Area Under Curve; Creatinine; Diuretics; Double-Blind Method; Drug Administrati | 2011 |
Diuretic strategies in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Area Under Curve; Creatinine; Diuretics; Double-Blind Method; Drug Administrati | 2011 |
Diuretic strategies in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Area Under Curve; Creatinine; Diuretics; Double-Blind Method; Drug Administrati | 2011 |
Diuretic strategies in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Area Under Curve; Creatinine; Diuretics; Double-Blind Method; Drug Administrati | 2011 |
Diuretic strategies in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Area Under Curve; Creatinine; Diuretics; Double-Blind Method; Drug Administrati | 2011 |
Diuretic strategies in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Area Under Curve; Creatinine; Diuretics; Double-Blind Method; Drug Administrati | 2011 |
Diuretic strategies in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Area Under Curve; Creatinine; Diuretics; Double-Blind Method; Drug Administrati | 2011 |
Diuretic strategies in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Area Under Curve; Creatinine; Diuretics; Double-Blind Method; Drug Administrati | 2011 |
Diuretic strategies in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Area Under Curve; Creatinine; Diuretics; Double-Blind Method; Drug Administrati | 2011 |
Diuretic strategies in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Area Under Curve; Creatinine; Diuretics; Double-Blind Method; Drug Administrati | 2011 |
Diuretic strategies in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Area Under Curve; Creatinine; Diuretics; Double-Blind Method; Drug Administrati | 2011 |
Diuretic strategies in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Area Under Curve; Creatinine; Diuretics; Double-Blind Method; Drug Administrati | 2011 |
Diuretic strategies in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Area Under Curve; Creatinine; Diuretics; Double-Blind Method; Drug Administrati | 2011 |
Diuretic strategies in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Area Under Curve; Creatinine; Diuretics; Double-Blind Method; Drug Administrati | 2011 |
Diuretic strategies in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Area Under Curve; Creatinine; Diuretics; Double-Blind Method; Drug Administrati | 2011 |
Diuretic strategies in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Area Under Curve; Creatinine; Diuretics; Double-Blind Method; Drug Administrati | 2011 |
Diuretic strategies in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Area Under Curve; Creatinine; Diuretics; Double-Blind Method; Drug Administrati | 2011 |
Diuretic strategies in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Area Under Curve; Creatinine; Diuretics; Double-Blind Method; Drug Administrati | 2011 |
Diuretic strategies in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Area Under Curve; Creatinine; Diuretics; Double-Blind Method; Drug Administrati | 2011 |
Diuretic strategies in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Area Under Curve; Creatinine; Diuretics; Double-Blind Method; Drug Administrati | 2011 |
Diuretic strategies in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Area Under Curve; Creatinine; Diuretics; Double-Blind Method; Drug Administrati | 2011 |
Diuretic strategies in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Area Under Curve; Creatinine; Diuretics; Double-Blind Method; Drug Administrati | 2011 |
Usefulness of lung impedance-guided pre-emptive therapy to prevent pulmonary edema during ST-elevation myocardial infarction and to improve long-term outcomes.
Topics: Age Factors; Diabetes Mellitus; Diuretics; Dyspnea; Electric Impedance; Female; Furosemide; Heart Ra | 2012 |
Effects of inhaled furosemide on CO(2) ventilatory responsiveness in humans.
Topics: Administration, Inhalation; Adult; Carbon Dioxide; Chemoreceptor Cells; Cross-Over Studies; Diuretic | 2002 |
Re: nebulized furosemide for dyspnea in terminal cancer patients.
Topics: Aged; Aged, 80 and over; Dyspnea; Female; Furosemide; Humans; Male; Middle Aged; Nebulizers and Vapo | 2002 |
Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Aged; Anthropometry; Attitude to Health; Cross-Over Studies; Diuretics; | 2004 |
Effect of inhaled furosemide on air hunger induced in healthy humans.
Topics: Administration, Inhalation; Adolescent; Adult; Analysis of Variance; Cross-Over Studies; Double-Blin | 2007 |
Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD.
Topics: Administration, Inhalation; Adult; Aged; Cross-Over Studies; Double-Blind Method; Dyspnea; Exercise | 2008 |
Randomised, placebo controlled trial of nebulised furosemide for breathlessness in patients with cancer.
Topics: Administration, Inhalation; Aged; Cross-Over Studies; Diuretics; Double-Blind Method; Dyspnea; Exerc | 2008 |
Inhaled furosemide greatly alleviates the sensation of experimentally induced dyspnea.
Topics: Administration, Inhalation; Adult; Cross-Over Studies; Double-Blind Method; Dyspnea; Female; Furosem | 2000 |
Furosemide-induced disturbances of renal function in patients undergoing TURP.
Topics: Aged; Aldosterone; Chlorides; Creatinine; Diuresis; Dyspnea; Furosemide; Humans; Hyponatremia; Male; | 1990 |
51 other studies available for furosemide and Dyspnea
| Article | Year |
|---|---|
A 50-Year-Old Woman With Shortness of Breath.
Topics: Azygos Vein; Diuretics; Dyspnea; Esophageal and Gastric Varices; Female; Furosemide; Hepatitis C; Hu | 2021 |
What is causing this patient's recurrent cough and dyspnea?
Topics: Adrenergic beta-Antagonists; Adult; Bundle-Branch Block; Cough; Diagnosis, Differential; Dyspnea; Ec | 2020 |
A rare case of biventricular non-compaction.
Topics: Cardiomyopathies; Carvedilol; Coronary Artery Disease; Dyspnea; Furosemide; Heart Failure; Heart Ven | 2020 |
Severe acute respiratory syndrome coronavirus-2- or pregnancy-related cardiomyopathy, a differential to be considered in the current pandemic: a case report.
Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Azithromycin; Cardiomyopathies; Cesarean Section; Co | 2021 |
Aerosol furosemide for dyspnea: High-dose controlled delivery does not improve effectiveness.
Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Albuterol; Dose-Response Relationship, Drug | 2018 |
Swimming-induced pulmonary oedema an uncommon condition diagnosed with POCUS ultrasound.
Topics: Adult; Angiography; Diuretics; Diving; Dyspnea; Female; Furosemide; Humans; Physical Exertion; Point | 2017 |
Iodinated Contrast Administration Resulting in Cardiogenic Shock in Patient with Uncontrolled Graves Disease.
Topics: Administration, Intravenous; Adult; Aortic Aneurysm; Atrial Fibrillation; Computed Tomography Angiog | 2017 |
An uncommon cause of dyspnea in the emergency department.
Topics: Adult; Chest Pain; Computed Tomography Angiography; Diagnosis, Differential; Dyspnea; Electrocardiog | 2018 |
66-Year-Old Man With Light-headedness, Chest Pain, and Dyspnea.
Topics: Aged; Calcium; Chest Pain; Diagnosis, Differential; Diuretics; Dizziness; Dyspnea; Furosemide; Human | 2019 |
Unilateral pulmonary oedema.
Topics: Acute Coronary Syndrome; Administration, Intravenous; Aged; Angioplasty; Diuretics; Dyspnea; Furosem | 2019 |
Caesarian dissection: a case of chest pain and dyspnea during delivery.
Topics: Adult; Cesarean Section; Chest Pain; Diuretics; Dyspnea; Female; Furosemide; Humans; Hypoxia; Infant | 2013 |
Metabolic alkalosis in a patient with dyspnoea.
Topics: Acidosis; Asthma; Diuretics; Dyspnea; Female; Furosemide; Humans; Hypercapnia; Middle Aged; Pneumoni | 2013 |
Isolated right ventricular cardiomyopathy with autoimmune hypothyroidism: a rare association in an adolescent.
Topics: Acenocoumarol; Adolescent; Anti-Arrhythmia Agents; Anticoagulants; Cardiomyopathies; Digoxin; Diuret | 2015 |
A 12-year-old boy with dyspnea, hypertension, hematuria, and proteinuria.
Topics: Child; Diagnosis, Differential; Dyspnea; Furosemide; Glomerulonephritis; Hematuria; Humans; Hyperten | 2015 |
Hyperthyroidism as a reversible cause of right ventricular overload and congestive heart failure.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Dyspnea; Echocardiography, Transesophageal; | 2008 |
[Dyspnea secondary to pulmonary hypertension in a patient with splenic myeloid metaplasia].
Topics: Anticoagulants; Cardiac Catheterization; Diagnosis, Differential; Diuretics; Drug Therapy, Combinati | 2009 |
Case of the month. Idiopathic dilated cardiomyopathy.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Angiography; Angiotensin-Converting | 2009 |
Nebulised frusemide for the symptomatic treatment of end-stage congestive heart failure.
Topics: Aged, 80 and over; Diuretics; Dyspnea; Furosemide; Heart Failure; Humans; Male; Nebulizers and Vapor | 2010 |
Diuretic strategies in patients with acute heart failure.
Topics: Confounding Factors, Epidemiologic; Diuretics; Dyspnea; Furosemide; Heart Failure; Humans; Outcome A | 2011 |
Cardiac AA amyloidosis in a patient with rheumatoid arthritis and systemic sclerosis: the therapeutic potential of biological reagents.
Topics: Aged; Amyloidosis; Antibodies, Antinuclear; Antirheumatic Agents; Arthritis, Rheumatoid; Benzimidazo | 2011 |
Diagnosis by treatment.
Topics: Acquired Immunodeficiency Syndrome; Beriberi; Cardiomyopathies; Colonoscopy; Diarrhea; Dyspnea; Fema | 2011 |
Preventing maternal death: 10 clinical diamonds.
Topics: Angiography; Antihypertensive Agents; Blood Transfusion; Chest Pain; Contraindications; Diuretics; D | 2012 |
Intravenous diuretic day-care treatment for patients with heart failure.
Topics: Aged; Aged, 80 and over; Cost Savings; Day Care, Medical; Disease Management; Disease Progression; D | 2012 |
95-year-old woman with sudden-onset dyspnea.
Topics: Aged, 80 and over; Atrial Fibrillation; Diuretics; Dyspnea; Female; Furosemide; Humans; Pulmonary Ed | 2012 |
Pulmonary arterial hypertension associated with neurofibromatosis type 1.
Topics: Aged; Anticoagulants; Combined Modality Therapy; Diuretics; Dyspnea; Fatal Outcome; Female; Follow-U | 2010 |
Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure.
Topics: Acute Disease; Aged; Biomarkers; Chi-Square Distribution; Diuretics; Drug Administration Schedule; D | 2013 |
Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure.
Topics: Acute Disease; Aged; Biomarkers; Chi-Square Distribution; Diuretics; Drug Administration Schedule; D | 2013 |
Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure.
Topics: Acute Disease; Aged; Biomarkers; Chi-Square Distribution; Diuretics; Drug Administration Schedule; D | 2013 |
Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure.
Topics: Acute Disease; Aged; Biomarkers; Chi-Square Distribution; Diuretics; Drug Administration Schedule; D | 2013 |
An 82-year-old woman with progressive dyspnea and bilateral infiltrates.
Topics: Aged, 80 and over; Disease Progression; Diuretics; Dyspnea; Female; Furosemide; Heart Failure; Human | 2013 |
Recombinant interferon alfa 2a in hepatic hemangiomatosis with congestive heart failure: a case report.
Topics: Abdominal Neoplasms; Angiogenesis Inhibitors; Digitalis Glycosides; Diuretics; Dyspnea; Female; Furo | 2003 |
A patient with chaotic atrial tachycardia.
Topics: Abnormalities, Multiple; Adenosine; Anti-Asthmatic Agents; Asthma; Bronchiolitis; Combined Modality | 2003 |
PAROXYSMAL NOCTURNAL DYSPNOEA.
Topics: Diuretics; Drug Therapy; Dyspnea; Dyspnea, Paroxysmal; Ethacrynic Acid; Furosemide; Geriatrics; Huma | 1965 |
Effect of nebulized furosemide in terminally ill cancer patients with dyspnea.
Topics: Chloride Channels; Critical Illness; Dyspnea; Furosemide; Humans; Nebulizers and Vaporizers; Neoplas | 2003 |
A 74-year-old woman with increasing dyspnea. Wet berberi with fulminant (Shoshin) cardiac failure and elevated troponin I.
Topics: Aged; Beriberi; Drug Therapy, Combination; Dyspnea; Female; Furosemide; Heart Failure; Humans; Thiam | 2006 |
Cardiorespiratory symptoms in pregnancy: not always pulmonary embolism.
Topics: Cardiomyopathies; Cesarean Section; Chest Pain; Diagnosis, Differential; Diuretics; Dyspnea; Echocar | 2007 |
A swimmer's wheeze.
Topics: Adult; Diuretics; Dyspnea; Exercise Tolerance; Female; Furosemide; Hemoptysis; Humans; Hypoxia; Oxyg | 2006 |
Breathlessness in cancer patients.
Topics: Administration, Inhalation; Analgesics, Opioid; Benzodiazepines; Bronchodilator Agents; Chemorecepto | 2008 |
[Primary systemic amyloidosis with cardiac manifestations].
Topics: Aged; Amyloidosis; Cardiomyopathy, Restrictive; Dyspnea; Echocardiography; Electrocardiography; Fema | 1995 |
A new visual analogue scale for assessment of dyspnoea in congestive heart failure.
Topics: Dyspnea; Furosemide; Heart Failure; Humans; Injections, Intravenous; Male; Pain Measurement; Quality | 1994 |
Nebulized frusemide for dyspnoea.
Topics: Administration, Inhalation; Dyspnea; Furosemide; Humans; Lung Neoplasms; Male; Nebulizers and Vapori | 1994 |
[Acute mitral insufficiency in osteogenesis imperfecta].
Topics: Aortic Valve; Captopril; Cardiac Catheterization; Drug Therapy, Combination; Dyspnea; Echocardiograp | 1994 |
[Drug-induced autoimmune disease due to furosemide?].
Topics: Aged; Collagen Diseases; Diuretics; Dyspnea; Furosemide; Humans; Male | 1997 |
Dilated cardiomyopathy in an American cocker spaniel with taurine deficiency.
Topics: Animals; Antihypertensive Agents; Breeding; Cardiomyopathy, Dilated; Cardiotonic Agents; Digoxin; Di | 1997 |
Iatrogenic acute hyponatraemia in a college athlete.
Topics: Acute Disease; Adult; Confusion; Dehydration; Diagnosis, Differential; Diuretics; Dyspnea; Fluid The | 1998 |
A case of eosinophilic myocarditis complicated by Kimura's disease (eosinophilic hyperplastic lymphogranuloma) and erythroderma.
Topics: Angiolymphoid Hyperplasia with Eosinophilia; Anti-Inflammatory Agents; Biopsy; Cardiomegaly; Dermati | 1999 |
Chronic eosinophilic pneumonia with pleural effusion.
Topics: Aged; Biopsy; Captopril; Chronic Disease; Dyspnea; Female; Furosemide; Heart Failure; Humans; Lung; | 1999 |
[Unclear lactate acidosis in a patient with heart failure under long-term diuretic therapy].
Topics: Acidosis, Lactic; Aged; Aged, 80 and over; Diuretics; Dyspnea; Furosemide; Heart Failure; Humans; La | 2000 |
Acute congestive heart failure associated with a limited form of systemic sclerosis and primary biliary cirrhosis.
Topics: Acute Disease; Antibody Specificity; Autoantibodies; Autoimmune Diseases; Centromere; Coronary Circu | 2001 |
Nebulized furosemide as a novel treatment for dyspnea in terminal cancer patients.
Topics: Administration, Inhalation; Diuretics; Dyspnea; Furosemide; Humans; Male; Middle Aged; Nebulizers an | 2002 |
[10 years' diuretic therapy and its complications].
Topics: Acetazolamide; Acidosis; Alkalosis; Anuria; Benzothiadiazines; Carbonic Anhydrase Inhibitors; Coma; | 1974 |
Unilateral pulmonary edema.
Topics: Aged; Aminophylline; Digitalis Glycosides; Dyspnea; Furosemide; Glucose; Humans; Injections, Intramu | 1974 |
Respiratory distress syndrome in the adult after cardiopulmonary bypass. A successful therapeutic approach.
Topics: Age Factors; Aged; Anti-Bacterial Agents; Dyspnea; Extracorporeal Circulation; Female; Furosemide; H | 1973 |
[Comparative evaluation of the action of furantryl and bloodletting on the blood gas composition and acid-base equilibrium during treatment of experimental pulmonary edema].
Topics: Acid-Base Equilibrium; Animals; Blood Gas Analysis; Bloodletting; Diuretics; Dyspnea; Epinephrine; F | 1972 |